期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Effect of Rifapentine and Rifampicin on Anti-Tuberculosis
1
作者 Weijia Lin Yaping Zhang +3 位作者 Zhi Liu Ping Feng Zhihua Zhang Xiulong Zhang 《Journal of Tuberculosis Research》 2021年第3期205-210,共6页
<b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To investigate the clinical effect of rifapentine and rifampicin in the ... <b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> To investigate the clinical effect of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.</span><b> </b><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"></span></b><b> </b><span style="font-family:Verdana;">Seventy-two cases of patients with initial treatment of pulmonary tuberculosis who attended the First Hos</span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">pital Affiliated to Hebei North </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">University</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> from February 2017 to August 2019 we</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">re </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">selected. They were randomly divided into observation group and control gro</span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">up, with 36 cases in each group. The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol. The symptom relief, image absorption and adverse reactions were compared between the two groups. <b></b></span><b><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"></span></b><span style="font-family:Verdana;"> The rate of symp</span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">tom relief was 86.11% in the observation group and 94.44% in the control</span><span><span style="font-family:Verdana;"> group, P < 0.05, which was statistically significant. Rifampin was more helpful than rifapentine in relieving clinical symptoms</span><span style="font-family:Verdana;">. The lesion absorption rate was 77.79% in the observation group and 88.89% in the control group, P < 0.05, and the difference was statistically significant. Rifampin was more beneficial to the absorption of TB lesions than rifapentine. The incidence of adverse reactions in the observation group was 16.67% much lower than that in the control group, which was 38.89%, indicating that the adverse reactions of rifapentine were less. <b></b></span><b><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"></span></b></span><b> </b><span style="font-family:Verdana;">Rifampicin is superior to rifapentine in clinical symptom relief and lesion absorption, but the incidence of adverse reactions is high.</span></span></span></span> 展开更多
关键词 RIFAMPICIN rifapentine Pulmonary Tuberculosis
下载PDF
抗结核新药Rifapentine在欧洲被定为罕见病治疗药物
2
作者 张翼 《药品评价》 CAS 2010年第20期60-60,共1页
赛诺菲-安万特肺结核药Rifapentine被欧盟委员会指定为罕见病治疗药物。Rifapentine属于利福霉素类产品,但在治疗分支杆菌性肺结核时效果更好,药物半衰期也更长,有助于提高患者依从性。目前这种药物已在美国有售,适应证为普通肺结... 赛诺菲-安万特肺结核药Rifapentine被欧盟委员会指定为罕见病治疗药物。Rifapentine属于利福霉素类产品,但在治疗分支杆菌性肺结核时效果更好,药物半衰期也更长,有助于提高患者依从性。目前这种药物已在美国有售,适应证为普通肺结核及药物敏感型肺结核,使用过程中与标准药联用疗程6个月。 展开更多
关键词 rifapentine 治疗药物 罕见病 抗结核 欧洲 新药 欧盟委员会 利福霉素类
下载PDF
抗结核药——Rifapentine(利福喷汀)
3
作者 梁金强 《国外新药介绍》 2000年第3期15-21,共7页
关键词 抗结核药 rifapentine 利福喷汀 药效学
下载PDF
Crystal modification of rifapentine using different solvents 被引量:1
4
作者 Kun ZHOU Jun LI +1 位作者 Jianhong LUO Dongsheng ZHENG 《Frontiers of Chemical Science and Engineering》 SCIE EI CSCD 2010年第1期65-69,共5页
Rifapentine crystals with different habits were prepared by recrystallization from selected solvents,such as methanol,ethanol,chloroform,and acetic acid.Scanning electron microscopy,X-ray powder diffractometry,infrare... Rifapentine crystals with different habits were prepared by recrystallization from selected solvents,such as methanol,ethanol,chloroform,and acetic acid.Scanning electron microscopy,X-ray powder diffractometry,infrared spectrometry,and differential scanning calorimetry were used to investigate the physicochemical characteristics of the prepared crystals.The comparative dissolution behaviors of the newly developed crystals and of rifapentine without being treated were also studied.Results show that the newly developed crystals were different from each other with respect to physical properties but were identical chemically.Needle-shaped crystals were obtained from methanol,ethanol,and chloroform solvents,and the block-shaped crystals were obtained from acetic acid solvent.X-ray diffraction spectra and differential scanning calorimetry investigation on those developed crystals clearly indicate that rifapentine has different crystal structure modification.When the crystal was obtained from acetic acid,the change of crystal habit was originated from the crystal structure modification.The dissolution rate of newly developed crystals was found to be higher than that of rifapentine without being treated.However,the modified crystal obtained from acetic acid shows the lower dissolution rate than crystals obtained from other solvents. 展开更多
关键词 rifapentine RECRYSTALLIZATION physicochemical characterization
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部